A multicenter phase III randomized study of 153Sm-EDTMP and Docetaxel + Prednisone versus Docetaxel + Prednisone in Taxane-naive patients with metastatic hormone-refractory prostate cancer.

Trial Profile

A multicenter phase III randomized study of 153Sm-EDTMP and Docetaxel + Prednisone versus Docetaxel + Prednisone in Taxane-naive patients with metastatic hormone-refractory prostate cancer.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 23 May 2014

At a glance

  • Drugs Samarium-153-SM-lexidronam (Primary) ; Docetaxel; Prednisone
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms SAMDOCET
  • Most Recent Events

    • 06 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top